Description: Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Home Page: www.axsome.com
22 Cortlandt Street
New York,
NY
10007
United States
Phone:
212 332 3241
Officers
| Name | Title |
|---|---|
| Dr. Herriot Tabuteau M.D. | Founder, Chairman, CEO & Pres |
| Mr. Nick Pizzie CPA, M.B.A. | Chief Financial Officer |
| Mr. Mark L. Jacobson | COO & Sec. |
| Mr. Hunter Murdock Esq. | Exec. VP of Legal & Compliance |
| Dr. Amanda Jones Pharm.D. | Sr. VP of Clinical Devel. |
| Ms. Lori Englebert M.B.A. | Exec. VP of Commercial & Bus. Devel. |
| Mr. Kevin Laliberte Pharm.D. | Exec. VP of Product Strategy |
| Joseph Debrah-Afful CPA, M.B.A. | Director of Fin. |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 21.1751 |
| Price-to-Sales TTM: | 125.0555 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 352 |